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Background/Aims: Short hemofilter survival and anticoagulation-related life-threatening complications are major
problems in systemic anticoagulation with heparin (SAH) for continuous renal replacement therapy (CRRT). The
present study examined if regional anticoagulation with citrate (RAC) using commercially available solutions can
overcome the associated problems of SAH to produce economical benefits. 
Methods: Forty-six patients were assigned to receive SAH or RAC. We assessed the coagulation state, clinical
outcomes, and adverse events. A Kaplan-Meier analysis was used to estimate hemofilter life span. The economi-
cal benefit related to the prolonged hemofilter survival was examined on the basis of the average daily cost.
Results: The mean age of patients was 66.5 ± 13.8 years and the majority were male (60.9%). While elective
discontinuation was most common cause of early CRRT interruption in the RAC group (34.3%, p < 0.01),
hemofilter clotting was most prevalent in the SAH group (82.2%, p < 0.01). The patient metabolic and electrolyte
control and survival rate were not different between the two groups. When compared with the RAC group, the
anticoagulation-associated bleeding was a major complication in the SAH group (15.0% vs. 61.5%, p < 0.01).
Regional anticoagulated hemofilters displayed a significantly longer survival time than systemic anticoagulated
hemofilters (59.5 ± 3.8 hr vs. 15.6 ± 1.3 hr, p < 0.01). Accordingly, the mean daily continuous venovenous
hemodiafiltration costs in the RAC and SAH groups were $575 ± 268 and $1,209 ± 517, respectively (p < 0.01).
Conclusions: RAC prolonged hemofilter survival, displaying an economical benefit without severe adverse
effects. The present study therefore demonstrates that RAC, using commercially available solutions, may be
advantageous over SAH as a cost-effective treatment in CRRT. (Korean J Intern Med 2011;26:68-75)
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INTRODUCTION
In Korea, continuous renal replacement therapy (CRRT)
is widely applied to patients in treating hemodynamically
unstable acute renal failure (ARF). While systemic antico-
agulation with heparin (SAH) is most frequently used, its
complications are poorly tolerated in critically ill patients.
Citrate displays anticoagulation properties through chelat-
ing ionized calcium and inducing deep hypocalcemia in the
hemofilter, without systemic bleeding complications.
Regional anticoagulation with citrate (RAC) has been
increasingly employed for the anticoagulation modality in
CRRT [1]. Despite the merits of RAC; its widespread imple-
mentation has been hindered by a lack of convenient meth-
ods and complexity of patient monitoring [2].
CRRT is a very expensive procedure; an expensivePark JS, et al. Regional anticoagulation with citrate    69
hemofilter and circuit in addition to a large volume of fluid
are required and the National Health Insurance
Cooperation (NHIC) does not insure additional hemofilter-
related costs. In addition, over-coagulation may lead to
severe complications including cerebral or gastrointestinal
hemorrhage while under-coagulation can lead to an early
interruption of the CRRT session. All of these conditions
have a direct impact on medical costs as patients with ARF
have an increased utilization of health care resources. 
The methodological and economical problems in current
CRRT highlight the requirement of efficient anticoagula-
tion procedures to prevent the clotting of the extracorpore-
al circuit, reducing CRRT-related medical costs without
severe complications. When compared with conventional
pharmacy-produced compounds, anticoagulation proto-
cols that utilize the regional anticoagulation properties of
citrate would be expected to improve the current anticoag-
ulation modality, minimizing medical costs in the process.
However, little data exist regarding the suitability of RAC
protocols in CRRT and its superiority to SAH in terms of
safety and medical costs. To address this issue, we designed
a RAC protocol using an Anticoagulant Citrate Dextrose
Formula A (ACD-A
®, Baxter, Deerfield, IL, USA) solution
and calcium gluconate (CG; ChoongWae Pharma Co.,
Seoul, Korea).
METHODS
Study population
From a total of 1,790 patients admitted to the intensive
care unit at the Hanyang University Hospital from
January 2006 to December 2007, 97 required CRRT as a
renal replacement therapy. We excluded patients with
advanced liver disease and cirrhosis or severe coagulation
disorders from the study. During this study, the SAH was
performed as a first choice treatment, and the RAC was
chosen as anticoagulation for patients unable to use
heparin. Fifty-one patients used neither the SAH nor the
RAC and received complete anticoagulation-free CRRT
using saline flushing. Thus, our observational study was
based on 46 patients; 26 patients were assigned to receive
the SAH for a total of 1,435 hours and 20 patients were
assigned to receive the RAC for 1,333 hours.
Continuous Venovenous Hemodiafiltration
(CVVHDF) protocol
CVVHDF was performed using the PRISMA quadruple
pump system (Gambro Renal Products, Mirandola, Italy)
with an AN69 hollow fiber biocompatible membrane in a
predilution setting for all patients. Venovenous access was
obtained by inserting an 11 F 15-cm double-lumen GamCath
catheter (Gambro Kathetertechnik, Hechingen, Germany)
into a femoral vein.
The replacement solution, composed of 4,750 mL of
Hemosol B0 solution (Hospal, Lyon, France) combined
with 250 mL of Hemosol B0 5.88% HCO3Na solution
(Hospal), was delivered initially at a rate of 1,200 mL/hr.
The solution composition was adapted to the acid-base
status of the patient in the dialysate bag. In cases of hyper-
natremia (Na
+ > 145 mmol/L) or metabolic alkalosis (pH
> 7.5 or HCO3
- > 40 mmol/L), Hemosol B0 5.88%
HCO3Na solution was not added to the Hemosol B0 solu-
tion. Otherwise, the dialysate was made from 4,750 mL of
Hemosol B0 solution and 250 mL of Hemosol B0
5.88% HCO3Na solution. The dialysate was delivered ini-
tially at a rate of 1,200 mL/hr. Net ultrafiltration was
adjusted according to the patient’s condition by changing
the rate of total fluid input.
Anticoagulation protocols
In cases of SAH, the patients received an initial bolus of
2,000 U followed by an infusion of 500 U/hr. Subsequent
adjustments to the rate of heparin infusion were guided by
the activated partial thromboplastin time (aPTT) drawn
every 6 hours, based on a predefined nomogram that
aimed to maintain an aPTT of 40-45 seconds (Table 1).
Contraindications to the use of heparin included a prior
history of heparin-induced thrombocytopenia, heparin
allergy, intracranial hemorrhage within 3 months, gas-
trointestinal hemorrhage requiring a transfusion within 3
months, active bleeding or significant trauma within 3
days, and a platelet count < 40,000/mm
3. Regional anti-
coagulation was achieved using an ACD-A
® solution, con-
taining dextrose 2.45 g/dL, sodium citrate 2.2 g/dL, and
citric acid 730 mg/dL, which was infused proximal to the
hemofilter targeted to maintain a post-filter ionized calci-
Table 1. Continuous venovenous hemodiafiltration
nomogram to adjust the heparin infusion rate
aPTT, sec Rate change
< 40 Increase rate by 200 U/hr
40 - 45  No change in rate
> 45  Decrease rate by 100 U/hr
aPTT, activated partial thromboplastin time.70 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
um level (iCa
2+) between 0.25 and 0.35 mmol/L.
Contraindication to the use of the ACD-A
® solution
included a serum ionized calcium level of < 0.70 mmol/L,
a serum pH of > 7.6, and a serum sodium concentration of
> 160 mmol/L [3]. CG was selected as a calcium replace-
ment solution. CG (97.6 mmol/L) in 1 L of isotonic saline
was initially infused at a rate of 10 mL/hr (0.976
mmol/hr). The rate adjustments of anticoagulation and
calcium replacement solutions were made at 6 hours and
every 12 hours following (Tables 2 and 3). 
Follow-up and outcome measurements
Data collected at the initiation of CVVHDF included
demographics, clinical parameters, the Acute Physiology
and Chronic Health Evaluation II (APCHE II) score, and
the Liaño ARF severity of illness score. We additionally
assessed the hemofilter survival time, hemorrhagic
episodes, aPTT, and post-filter iCa
2+ levels. Serum elec-
trolytes, blood urea nitrogen and creatinine, arterial blood
gases, and platelet counts were measured at baseline, 1
and 6 hours, and every 12 hours following. Early termina-
tion was defined as any reason the full prescribed dose
was not administered in the first 24 hours. Successful
anticoagulation was achieved when heparin and citrate
were administered to achieve their target level at 24 hours
or later. Definitive bleeding was defined as an acute bleed-
ing episode and/or the need for transfusion of more than
2 units of packed red blood cells (PRC) within 48 hours.
Any incidence of hypotension (systolic blood pressure <
90 mmHg), and metabolic alkalosis (pH > 7.45 and base
excess > 3 mmol/L) or acidosis (pH < 7.35 and base
excess < -3 mmol/L) were recorded. We detected citrate
toxicity through monitoring the changes in serum pH,
sodium, bicarbonate, and iCa
2+ levels.
Cost analyses
The average daily costs of the CVVHDF were determined
as the cost to the hospital. Routine laboratory and care
costs, physician fees, and the capital cost of the treatment
were not included in this analysis as these payments are
identical irrespective of the anticoagulation method. The
costs of all dialysates and replacement solutions, hemofil-
ters, double-lumen catheters, concentrates, infusions,
transfusions, and disposables that were related to dialysis
were included. In the cases of early termination when the
hemofilter cost was not charged to insurance, we assigned
additional hemofilter costs to the prior costs.
Statistical analyses
The baseline characteristics are presented as the mean
± SD or as the proportion of patients in each group. The
comparisons between numeric variables were performed
using the Mann-Whitney U test. The chi-square test with
Fisher’s exact test was used to evaluate the association
between nominal variables. Repeated measurements of
the analysis of variance within the subject factor (time)
and between the subjects factor (group) was used. If the
assumed sphericity was not achieved, the Greenhouse-
Geisser adjusted pvalues were reported. The relationships
between one or more independent variables of interest
were analyzed by logistic regression. The time to hemofil-
ter failure was measured from the time of initiation to the
time of elective discontinuation (surgery) or spontaneous
failure (such as clotting). The elective discontinuations
were treated as censored data and spontaneous failures as
uncensored data. The Kaplan-Meier survival analyses
were used to present the results and generate the estimat-
ed mean times to hemofilter failure. The log-rank test was
used to compare the time to the hemofilter failure
between the groups. All p values were analyzed by a two-
sided test, and p values less than 0.05 were considered
statistically significant. All analyses were performed using
the SAS version 9.1 (SAS Inc., Cary, NC, USA).
Table 2. Continuous venovenous hemodiafiltration
nomogram to adjust the citrate infusion rate
Post-filter iCa
2+, mmol/L Rate change
< 0.25 Decrease rate by 10 mL/hr
0.25 - 0.35 No change in rate
0.35 - 0.45  Increase rate by 10 mL/hr
> 0.45  Increase rate by 20 mL/hr
iCa
2+, ionized calcium.
Table 3. Continuous venovenous hemodiafiltration
nomogram to adjust the calcium gluconate solution
infusion rate
Systemic iCa2+,mmol/L Rate change
< 0.75 Decrease rate by 4 mL/hr and Ca2+
10 mmol bolus over 1 hr
0.75 - 1.13 No change in rate
1.13 - 1.32  Increase rate by 2 mL/hr
> 1.32  Increase rate by 4 mL/hr
iCa
2+, ionized calcium.Park JS, et al. Regional anticoagulation with citrate    71
Table 4. Clinical and demographic features of patients at the initiation of CVVHDF
SAH RAC p value
(n = 26) (n = 20)
Age, yr 66.8 ± 11.2 64.9 ± 16.7 NS
Male 16 (61.5) 12 (60.0) NS
APACHE II 23.3 ± 4.8 30.6 ± 5.2 0.0031
Liaño ARF severity of illness score 63.5 ± 16.4 72.4 ± 21.7 NS
Septic acute tubular necrosis  10 (38.5) 8 (40.0) NS
Surgical acute tubular necrosis  0 2 (10.0) NS
Medical acute tubular necrosis  16 (61.5) 10 (50.0) NS
Hematocrit  29.8 ± 5.6 30.0 ± 6.0 NS
Platelet, /mm3 167.5 ± 101.7 129.7 ± 69.3 NS
Sodium, mmol/L 135.8 ± 5.1 136.9 ± 6.9 NS
Bicarbonate, mmol/L 17.3 ± 6.1 16.5 ± 5.8 NS
Arterial blood pH 7.33 ± 0.10 7.29 ± 0.15 NS
Plasma BUN, mg/dL 52.9 ± 30.7 56.9 ± 34.4 NS
Prothrombin time, INR 1.37 ± 0.05 1.15 ± 0.14 NS
Plasma creatinine, mg/dL 5.5 ± 2.9 4.0 ± 2.0 NS
Oliguria or anuria  9 (34.6) 14 (70.0) 0.0173
Required mechanical ventilator  15 (57.7) 11 (55.0) NS
Required vasopressor  16 (61.5) 9 (45.0) NS
Values are presented as mean ± SD or number (%). 
CVVHDF, continuous venovenous hemodiafiltration; SAH, systemic anticoagulation with unfractionated heparin; RAC, regional antico-
agulation with citrate; NS, not significant; APCHE II, Acute Physiology and Chronic Health Evaluation II; ARF, acute renal failure; BUN,
blood urea nitrogen; INR, international normalized ratio. 
Table 5. Reasons for hemofilter circuit discontinuation during CVVHDF
SAH RAC p value
(n = 101) (n = 35)
Hemofilter life span ≥ 72 hr  0 6 (17.1) 0.0002
Elective discontinuation  12 (11.9) 12 (34.3) 0.0027
Hemofilter clotting  83 (82.2) 11 (31.4) < 0.0001
High transmembranous pressure  1 (1.0) 2 (5.7) NS
Circuit failure  5 (4.9) 4 (11.4) NS
Values are presented as number (%). 
CVVHDF, continuous venovenous hemodiafiltration; SAH, systemic anticoagulation with unfractionated heparin; RAC, regional antico-
agulation with citrate; NS, not significant.
Table 6. Newly developed adverse events during CVVHDF
SAH RAC p value
(n = 26) (n = 20)
Bleeding episode  16 (61.5) 3 (15.0) 0.0023
Hypotension 9  (34.6) 1  (5.0) 0.0278
Metabolic acidosis  2 (7.7) 0 NS
Metabolic alkalosis  3 (11.5) 7 (35.0) NS
Values are presented as number (%). 
CVVHDF, continuous venovenous hemodiafiltration; SAH, systemic anticoagulation with unfractionated heparin; RAC, regional antico-
agulation with citrate; NS, not significant.72 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
RESULTS
Patient clinical characteristics
The clinical details of all 46 patients are listed in Table 4.
They consisted of 28 men and 18 women, with a mean age
of 66.5 ± 13.8 years. When compared with the SAH group,
those patients receiving RAC displayed greater organ fail-
ure (APACHE II scores, 23.3 ± 4.8 vs. 30.6 ± 5.2; p <
0.01) and more oligouric ARF (34.6% vs. 70.0%, p <
0.05), which was not associated with the anticoagulation
efficacy in this study (data not shown). No significant dif-
ferences were observed in other baseline characteristics
between the two groups.
Outcomes
In total, 136 hemofilters were included in the analysis:
101 receiving SAH and 35 receiving RAC. The reasons for
hemofilter termination in the RAC group were significant-
ly different from those in SAH group (Table 5); while elec-
tive discontinuation was the most common cause of early
CVVHDF interruption in the RAC group (34.3%, p <
0.01), hemofilter clotting was most common cause in the
SAH group (82.2%, p < 0.01). In addition, the hemofilter
survival rate up to 72 hours was higher in the RAC group
(0% vs. 17.1%, p < 0.01) when compared with the SAH
group.
The majority of hemofilters in the SAH group were ter-
minated before 24 hours, making a comparison of the
groups in terms of hemofilter-related outcomes difficult.
While RAC provided a good anticoagulation status for
more than 80.0% of the extracorporeal circuits through-
out the CVVHDF session, a wide inter- and intra-patient
variability of the aPTT values was evident in the SAH
group and the maintenance of target levels was difficult.
Furthermore, the aPTT data showed no association
between aPTT and hemofilter survival times following
subgroup analysis (r= -0.3546, p= 0.39). We observed no
differences between the two groups in terms of solute
removal (data not shown). 
No difference was observed in the patients’ survival at
day 30 following the termination of CVVHDF. The sur-
vival rate of the SAH group patients was 54.2% at 30 days
following cessation, compared to 50.0% in the RAC group.
Such findings can be explained as either a result of the
limitations of a single-center, case-controlled study, or
greater organ failure in the RAC group.
Adverse effects
We observed significant differences between newly
developed adverse events during the CVVHDF session
(Table 6). Gastrointestinal (GI) bleeding was the most
common adverse event. In the SAH group, seven of the
patients with GI bleeding displayed definitive anticoagula-
tion-associated bleeding and four of those patients
required a PRC transfusion for life-saving. Three patients
required a PRC transfusion of more than 2 units; one case
Figure 1. Metabolic and electrolyte control in CVVHDF for
patients receiving SAH and RAC. Repeated measurement analy-
sis of variance shows no difference between the two groups in
the light of hypernatremia or metabolic acid-base balance.
CVVHDF, continuous venovenous hemodiafiltration; SAH, sys-
temic anticoagulation with unfractionated heparin; RAC, region-
al anticoagulation with citrate.
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of intracranial hemorrhage and hematochezia, one case of
pulmonary hemorrhage, and four cases of large hematoma
at the needle puncture site were observed in the SAH
group. These patients were inevitably converted to the no-
anticoagulation method. In the RAC group, two patients
with congestive heart failure required a PRC transfusion
for anemia control and one patient displayed obscure GI
bleeding. 
Newly developed hypotensive episodes were more fre-
quently observed in the SAH group compared to the RAC
group (34.6% vs. 5.0%, p < 0.05). A Fisher’s exact test
revealed that a hypotensive event displayed a significant
association with bleeding complications (p < 0.05). In the
SAH group, eight patients displayed a hypotensive
episode accompanied by bleeding complications. Four
cases with GI bleeding occurred within 24 hours following
the hypotensive episodes; one case of large hematoma at
the needle puncture site occurred 11 hours prior to the
hypotensive episode and three patients displayed both GI
bleeding and oozing of the needle puncture site during
SAH. However, such events did not display an association
with the severity of the bleeding complication, namely the
levels of PRC transfusion (p> 0.05). 
The metabolic and electrolyte controls were relatively
stable during CVVHDF (Fig. 1). No episodes of citrate tox-
icity or hepatic dysfunction were observed in the RAC
group (data not shown).
Hemofilter survival and medical cost
A Kaplan-Meier analysis revealed that the hemofilter
survival time was longer in those patients treated with
RAC (SAH, 15.6 ± 1.3 hr; RAC, 59.5 ± 3.8 hr; log-rank, p<
0.01) (Table 7, Fig. 2). A life-table analysis showed that
74.0% of the hemofilter-receiving patients treated with
RAC were functional at 48 hours compared to only 3.8%
of those patients treated with SAH. 
During the observation period, RAC significantly
reduced the frequency of early CVVHDF termination
when compared to SAH (2 vs. 64, p < 0.01). Because the
Table 7. Characteristics of hemofilter by the type of anticoagulation
SAH RAC p value
Survival time of hemofilter, hr 15.6 ± 1.3 59.5 ± 3.8 < 0.0001
Total CVVHDF cost, $/day 1,209 ± 517 757 ± 268 0.0013
Hemofilter costs 628 ± 402 225 ± 138 0.0002
Insured cost 186 ± 131 162 ± 89 NS
Uninsured cost 442 ± 441 63 ± 76 < 0.0001
Replacement solution cost 183 ± 34 184 ± 26 NS
Anticoagulation cost 44 ± 60 83 ± 23 < 0.0001
Laboratory costs  299 ± 88 233 ± 69 0.0102
aPTT/iCa2+ cost 87 ± 21 82 ± 26 NS
Other laboratory costs 212 ± 68 151 ± 43 0.0023
Transfusion costs 55 ± 103 31 ± 92 NS
PRC transfusion cost 33 ± 58 11 ± 24 NS
Platelet transfusion cost 22 ± 80 21 ± 74 NS
Values are presented as mean ± SD.
SAH, systemic anticoagulation with unfractionated heparin; RAC, regional anticoagulation with citrate; CVVHDF, continuous venove-
nous hemodiafiltration; NS, not significant; aPTT, activated partial thromboplastin time; iCa
2+, ionized calcium; PRC, packed red cell.
Figure 2. Kaplan-Meier estimate curve for time to hemofilter fail-
ure according to the type of anticoagulation used. The hemofilter
survival rate was significantly higher in patients receiving RAC (p
< 0.01). Statistical significance was calculated using the log-rank
test. SAH, systemic anticoagulation with unfractionated heparin;
RAC, regional anticoagulation with citrate; circles, censored data.
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NHIC did not pay for additional hemofilter costs, unin-
sured hemofilter costs were significantly higher in the
SAH group compared to the RAC group ($442 ± 441 vs.
$63 ± 76, respectively; p < 0.01). As no differences in the
aPTT/iCa
2+ costs between both groups was evident, the
frequent evaluation of hemoglobin levels after the bleed-
ing episodes significantly increased other laboratory costs
in the SAH group (SAH, $212 ± 68; RAC, $151 ± 43; p <
0.01) (Table 7). Anticoagulation-related costs were higher
in the RAC group. The improvement in hemofilter sur-
vival time, the lower hemofilter-related costs, and the
fewer anticoagulation-associated complications mini-
mized the total CVVHDF cost (SAH, $1,209 ± 517/day;
RAC, $757 ± 268/day; p< 0.01).
DISCUSSION
In this study, we compared SAH with RAC using com-
mercially available solutions as an anticoagulation method
for the treatment of critically ill patients. We found that
the application of ACD-A
® solution and CG to the RAC
protocol prolonged the hemofilter life span and decreased
the frequency and severity of several complications when
compared to SAH. The efficacy was similar to other RAC
protocols using commercially available solutions [4,5]. Of
note, our RAC protocol (+ACD-A
® solution and CG)
would enable these patients to receive a cost-effective
renal replacement therapy without severe complications.
When considering the successful application of CRRT,
the maintenance of the patient extracorporeal circuit is a
major component. Unsuitable anticoagulation leads to
recurrent hemofilter clotting and frequent circuit replace-
ment. In addition, an increased cost and procedure work-
load, a prolonged “downtime”, a deterioration in azotemic
control, and an increased mortality are observed [6-9].
Alternatively over-coagulation leads to coagulation-relat-
ed complications, increased costs of care procedures, and
increased mortality. A variety of anticoagulation methods
have been prescribed including systemic heparin antico-
agulation, low-molecular-weight heparin, prostacyclin,
and nafamostat mesylate [10], of which SAH is the most
common, inexpensive, and easily applied method [11].
However, systemic heparin anticoagulation increases the
risk of life-threatening bleeding and hemorrhagic shock,
whereas SAH yields only a minimal hemofilter survival
time. Furthermore, we observed that heparin-induced
minor bleeding episodes raised the incidence of hypoten-
sion. Such findings indicate that even small levels of
bleeding may decrease the blood pressure of critically ill
patients, increase the requirement of vasopressor agents,
aggravate the clinical course, and make SAH unsuitable
for CRRT. While we did not perform a cost analysis
regarding hypotensive accidents and vasopressor agents,
these events would cause an additional medical expense.
Citrate infusion has been utilized in numerous clinical
trials based on its fundamental properties of regional anti-
coagulation that is fully reversible by calcium administra-
tion. In addition, the monitoring of hemofilter clotting is
fast and cost-effective as a measurement of ionized calci-
um. However, citrate infusion may expose patients to
metabolic complications including hypernatremia and
metabolic alkalosis [12]. Previous clinical trials using
pharmacy-based citrate solutions reported that the
episodes of metabolic alkalosis requiring treatment with
hydrochloric acid developed in up to 38% of critically ill
patients requiring CRRT [13]. Conversely, the present
study shows that the RAC protocol (+ACD-A
® solution
and CG) had a tendency to decrease heparin-associated
and pharmacy-made citrate-associated adverse events.
When compared to the SAH group, the frequency and
severity of several heparin-related complications in the
RAC group (including bleeding complications or hypoten-
sive episodes) were significantly reduced. In light of cit-
rate-related complications, seven instances of accidental
over-infusion of ACD-A
® occurred that led to metabolic
alkalosis. These were corrected by citrate infusion without
any influence on clinical outcomes. When compared with
previous clinical trials [1,12], other pharmacy-made cit-
rate-associated adverse events including hypernatermia,
extreme biochemical or hematological abnormalities, and
citrate toxicity were observed less frequently in the RAC
group. 
Regarding the hemofilter survival rate and reasons for
hemofilter/circuit failure, our findings were consistent
with previous studies demonstrating the superiority of
RAC to SAH [3,6,10]. Cointault and colleagues reported
that the ACD-A
® solution with calcium chloride creates an
additional anticoagulation-related cost and that RAC
using commercially available solutions would be an
expensive procedure [4]. When considering the anticoag-
ulation-related costs for the maintenance of a single CRRT
session, SAH is an inexpensive and easily administered
method while RAC requires numerous expensive
Hemosol
® solutions and additional replacement solutions.
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patients are composed of multiple sessions and that SAH
induces life-threatening complications and frequent
hemofilter clotting. RAC using commercially available
solutions decreases the requirement of pharmacy-based
solutions providing a significant improvement in bedside
care and the severity of complications [4,14]. RAC may
thus establish true regional circuit anticoagulation and
minimize the SAH associated economical burden.
In conclusion, to assess a beneficial anticoagulation
method for CRRT, we conducted an observational study
to evaluate the efficacy, safety, and economic aspects of
RAC using commercially available solutions in Korea.
Although this study was a single-center cross-sectional
analysis, we postulate that the combination of ACD-A
®
solution and CG is an attractive method to prolong the
hemofilter survival time and minimize the complications
and economical burden of SAH, particularly in those
patients with a high risk of bleeding. 
Conflict of interest 
No potential conflict of interest relevant to this article
was reported.
REFERENCES
1.  Palsson R, Niles JL. Regional citrate anticoagulation in continu-
ous venovenous hemofiltration in critically ill patients with a high
risk of bleeding. Kidney Int 1999;55:1991-1997.
2. Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A
practical citrate anticoagulation continuous venovenous hemodi-
afiltration protocol for metabolic control and high solute clear-
ance. Clin J Am Soc Nephrol 2006;1:79-87.
3. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate
versus systemic heparin anticoagulation for continuous renal
replacement in critically ill patients. Kidney Int 2005;67:2361-
2367.
4. Cointault O, Kamar N, Bories P, et al. Regional citrate anticoagu-
lation in continuous venovenous haemodiafiltration using com-
mercial solutions. Nephrol Dial Transplant 2004;19:171-178.
5.  Munjal S, Ejaz AA. Regional citrate anticoagulation in continuous
venovenous haemofiltration using commercial preparations.
Nephrology (Carlton) 2006;11:405-409.
6. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B,
Damas P. Citrate vs. heparin for anticoagulation in continuous
venovenous hemofiltration: a prospective randomized study.
Intensive Care Med 2004;30:260-265.
7. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in
continuous veno-venous haemofiltration on outcomes of acute
renal failure: a prospective randomised trial. Lancet
2000;356:26-30.
8. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous
hemofiltration without anticoagulation in high-risk patients.
Intensive Care Med 2000;26:1652-1657.
9. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R.
Continuous is not continuous: the incidence and impact of circuit
“down-time” on uraemic control during continuous veno-venous
haemofiltration. Intensive Care Med 2003;29:575-578.
10. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T. Is
regional citrate superior to systemic heparin anticoagulation for
continuous renal replacement therapy? A prospective observa-
tional study in an adult regional critical care system. J Crit Care
2005;20:155-161.
11.  Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal
replacement therapy: a worldwide practice survey. The beginning
and ending supportive therapy for the kidney (B.E.S.T. kidney)
investigators. Intensive Care Med 2007;33:1563-1570.
12. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG.
Simplified citrate anticoagulation for continuous renal replace-
ment therapy. Kidney Int 2001;60:370-374.
13. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional cit-
rate anticoagulation for continuous arteriovenous hemodialysis
in critically ill patients. Kidney Int 1990;38:976-981.
14. Brophy PD, Somers MJ, Baum MA, et al. Multi-centre evaluation
of anticoagulation in patients receiving continuous renal replace-
ment therapy (CRRT). Nephrol Dial Transplant 2005;20:1416-
1421.